Department of Molecular Genetics, Inserm U614, Institute for Biomedical Research and Innovation, University of Rouen, Rouen, France.
Mol Psychiatry. 2012 Sep;17(9):875-9. doi: 10.1038/mp.2012.15. Epub 2012 Apr 3.
Performing exome sequencing in 14 autosomal dominant early-onset Alzheimer disease (ADEOAD) index cases without mutation on known genes (amyloid precursor protein (APP), presenilin1 (PSEN1) and presenilin2 (PSEN2)), we found that in five patients, the SORL1 gene harbored unknown nonsense (n=1) or missense (n=4) mutations. These mutations were not retrieved in 1500 controls of same ethnic origin. In a replication sample, including 15 ADEOAD cases, 2 unknown non-synonymous mutations (1 missense, 1 nonsense) were retrieved, thus yielding to a total of 7/29 unknown mutations in the combined sample. Using in silico predictions, we conclude that these seven private mutations are likely to have a pathogenic effect. SORL1 encodes the Sortilin-related receptor LR11/SorLA, a protein involved in the control of amyloid beta peptide production. Our results suggest that besides the involvement of the APP and PSEN genes, further genetic heterogeneity, involving another gene of the same pathway is present in ADEOAD.
在 14 名常染色体显性早发性阿尔茨海默病(ADEOAD)指数病例中进行外显子组测序,这些病例在已知基因(淀粉样前体蛋白 (APP)、早老素 1 (PSEN1) 和早老素 2 (PSEN2))上没有突变,我们发现 5 名患者的 SORL1 基因携带未知的无义(n=1)或错义(n=4)突变。这些突变在相同种族来源的 1500 名对照中未被检出。在包括 15 名 ADEOAD 病例的复制样本中,检索到 2 个未知的非同义突变(1 个错义,1 个无义),因此在合并样本中共有 7/29 个未知突变。通过计算预测,我们得出结论,这七个个体突变很可能具有致病性。SORL1 编码 Sortilin 相关受体 LR11/SorLA,这是一种参与控制淀粉样β肽产生的蛋白质。我们的研究结果表明,除了 APP 和 PSEN 基因的参与外,ADEOAD 中还存在涉及同一途径的另一个基因的遗传异质性。